Opposite effects of arsenic trioxide on the Nrf2 pathway in oral squamous cell carcinoma in vitro and in vivo

被引:21
作者
Zhang, Xinyan [1 ]
Su, Ying
Zhang, Min
Sun, Zheng
机构
[1] Capital Med Univ, Beijing Inst Dent Res, Beijing Stomatol Hosp, Beijing 100050, Peoples R China
关键词
Arsenic trioxide; Nrf2; Oral squamous cell carcinoma; INDUCED MALIGNANT-TRANSFORMATION; ANTIOXIDANT RESPONSE; CANCER CELLS; INDUCTION; APOPTOSIS; LINE; PML;
D O I
10.1016/j.canlet.2011.12.005
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Nuclear factor erythroid derived 2 like 2 (Nrf2) is a critical transcriptional factor in mediating cellular defense mechanisms against oxidative stress or electrophiles. Arsenic has been reported to induce malignant transformation of human cells through Nrf2-dependent signaling pathway. However, arsenic is also a promising cancer therapeutic drug for solid tumors, including oral squamous cell carcinoma (OSCC). It is still unclear how Nrf2 may mediate cellular response of OSCC cells when treated with arsenic. In order to fully understand the impact of arsenic on Nrf2 signaling in human OSCC, we examined expression of Nrf2 and Nrf2-regulated genes in arsenic trioxide (ATO)-treated OSCC cells in vitro and in ATO-treated OSCC xenografts. ATO had anti-cancer effects on both cultured OSCC cells and OSCC xenografts by inhibiting cell growth, suppressing angiogenesis and inducing apoptosis. ATO activated a silent Nrf2 pathway in cultured OSCC cells as shown by induction of Nrf2 and Nrf2-regulated genes, NAD(P)H:quinone oxidoreductase 1 (NQ01) and heme oxygenase-1 (HO-1), in a dose-dependent manner. On the contrary. Nrf2 pathway became active in OSCC xenograft tumors, and ATO treatment down-regulated expression of Nrf2 and Nrf2-regulated genes. Our study clearly demonstrated opposite effects of ATO on Nrf2 pathway in OSCC cells in vitro and in vivo. (C) 2011 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:93 / 98
页数:6
相关论文
共 27 条
[1]   Introduction: The history of arsenic trioxide in cancer therapy [J].
Antman, KH .
ONCOLOGIST, 2001, 6 :1-2
[2]   The cytoprotective role of the Keap1-Nrf2 pathway [J].
Baird, Liam ;
Dinkova-Kostova, Albena T. .
ARCHIVES OF TOXICOLOGY, 2011, 85 (04) :241-272
[3]   The paradox of arsenic: molecular mechanisms of cell transformation and chemotherapeutic effects [J].
Bode, AM ;
Dong, ZG .
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2002, 42 (01) :5-24
[4]   Arsenic Trioxide inhibits the growth of human ovarian carcinoma cell line [J].
Bornstein, J ;
Sagi, S ;
Haj, A ;
Harroch, J ;
Fares, F .
GYNECOLOGIC ONCOLOGY, 2005, 99 (03) :726-729
[5]   Phosphorylation of PML by mitogen-activated protein kinases plays a key role in arsenic trioxide-mediated apoptosis [J].
Hayakawa, F ;
Privalsky, ML .
CANCER CELL, 2004, 5 (04) :389-401
[6]   Arsenic induces NAD(P)H-quinone oxidoreductase I by disrupting the Nrf2•Keap1•CuI3 complex and recruiting Nrf2•Maf to the antioxidant response element enhancer [J].
He, Xiaoqing ;
Chen, Michael G. ;
Lin, Gary X. ;
Ma, Qiang .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (33) :23620-23631
[7]   Critical Cysteine Residues of Kelch-Like ECH-Associated Protein 1 in Arsenic Sensing and Suppression of Nuclear Factor Erythroid 2-Related Factor 2 [J].
He, Xiaoqing ;
Ma, Qiang .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2010, 332 (01) :66-75
[8]   NRF2 Cysteine Residues Are Critical for Oxidant/Electrophile-Sensing, Kelch-Like ECH-Associated Protein-1-Dependent Ubiquitination-Proteasomal Degradation, and Transcription Activation [J].
He, Xiaoqing ;
Ma, Qiang .
MOLECULAR PHARMACOLOGY, 2009, 76 (06) :1265-1278
[9]   Molecular mechanism activating Nrf2-Keap1 pathway in regulation of adaptive response to electrophiles [J].
Itoh, K ;
Tong, KI ;
Yamamoto, M .
FREE RADICAL BIOLOGY AND MEDICINE, 2004, 36 (10) :1208-1213
[10]   Nrf2: friend or foe for chemoprevention? [J].
Kensler, Thomas W. ;
Wakabayashi, Nobunao .
CARCINOGENESIS, 2010, 31 (01) :90-99